137 related articles for article (PubMed ID: 36931147)
21. BRAF V600E and RNF43 Co-mutations Predict Patient Outcomes With Targeted Therapies in Real-World Cases of Colorectal Cancer.
Quintanilha JCF; Graf RP; Oxnard GR
Oncologist; 2023 Mar; 28(3):e171-e174. PubMed ID: 36779536
[TBL] [Abstract][Full Text] [Related]
22. Monitoring tumour resistance to the BRAF inhibitor combination regimen in colorectal cancer patients via circulating tumour DNA.
Ye LF; Huang ZY; Chen XX; Chen ZG; Wu SX; Ren C; Hu MT; Bao H; Jin Y; Wang F; Wang FH; Du ZM; Wu X; Ju HQ; Shao Y; Li YH; Xu RH; Wang DS
Drug Resist Updat; 2022 Dec; 65():100883. PubMed ID: 36202008
[TBL] [Abstract][Full Text] [Related]
23. Circulating tumor DNA, and clinical features to guide rechallenge with BRAF inhibitors in BRAF-V600E mutated metastatic colorectal cancer.
Ros J; Vivancos A; Tabernero J; Élez E
Ann Oncol; 2024 Feb; 35(2):240-241. PubMed ID: 37866812
[No Abstract] [Full Text] [Related]
24.
Ros J; Baraibar I; Sardo E; Mulet N; Salvà F; Argilés G; Martini G; Ciardiello D; Cuadra JL; Tabernero J; Élez E
Ther Adv Med Oncol; 2021; 13():1758835921992974. PubMed ID: 33747149
[TBL] [Abstract][Full Text] [Related]
25. Novel prognostic implications of complement activation in the tumour microenvironment for de novo metastatic BRAF V600E mutant colorectal cancer.
Chen KH; Hsu CL; Su YL; Yuan CT; Lin LI; Tsai JH; Liang YH; Cheng AL; Yeh KH
Br J Cancer; 2023 Jan; 128(1):102-111. PubMed ID: 36319846
[TBL] [Abstract][Full Text] [Related]
26. Long-term Survival Update and Extended RAS Mutational Analysis of the CAIRO2 Trial: Addition of Cetuximab to CAPOX/Bevacizumab in Metastatic Colorectal Cancer.
Ten Hoorn S; Mol L; Sommeijer DW; Nijman L; van den Bosch T; de Back TR; Ylstra B; van Dijk E; van Noesel CJM; Reinten RJ; Nagtegaal ID; Koopman M; Punt CJA; Vermeulen L
Clin Colorectal Cancer; 2023 Mar; 22(1):67-75. PubMed ID: 36564280
[TBL] [Abstract][Full Text] [Related]
27. Treatment of Metastatic Colorectal Cancer: ASCO Guideline.
Morris VK; Kennedy EB; Baxter NN; Benson AB; Cercek A; Cho M; Ciombor KK; Cremolini C; Davis A; Deming DA; Fakih MG; Gholami S; Hong TS; Jaiyesimi I; Klute K; Lieu C; Sanoff H; Strickler JH; White S; Willis JA; Eng C
J Clin Oncol; 2023 Jan; 41(3):678-700. PubMed ID: 36252154
[TBL] [Abstract][Full Text] [Related]
28. Adverse Events Associated with Encorafenib Plus Cetuximab in Patients with BRAFV600E-mutant Metastatic Colorectal Cancer: An in-depth Analysis of the BEACON CRC Study.
Taieb J; Lonardi S; Desai J; Folprecht G; Gallois C; Marques EP; Khan S; Castagné C; Wasan H
Clin Colorectal Cancer; 2023 Mar; 22(1):59-66. PubMed ID: 36653241
[TBL] [Abstract][Full Text] [Related]
29. Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial.
Trouiller JB; Macabeo B; Poll A; Howard D; Buckland A; Sivignon M; Clay E; Malka D; Samalin E; Toumi M; Laramée P
BMJ Open; 2022 Nov; 12(11):e063700. PubMed ID: 36410812
[TBL] [Abstract][Full Text] [Related]
30. BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives.
Sanz-Garcia E; Argiles G; Elez E; Tabernero J
Ann Oncol; 2017 Nov; 28(11):2648-2657. PubMed ID: 29045527
[TBL] [Abstract][Full Text] [Related]
31. Management of
Takeda H; Sunakawa Y
Front Oncol; 2021; 11():602194. PubMed ID: 33842313
[No Abstract] [Full Text] [Related]
32. The Role of BRAF in Metastatic Colorectal Carcinoma-Past, Present, and Future.
Djanani A; Eller S; Öfner D; Troppmair J; Maglione M
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33256240
[TBL] [Abstract][Full Text] [Related]
33. Exploring the best treatment options for BRAF-mutant metastatic colon cancer.
Taieb J; Lapeyre-Prost A; Laurent Puig P; Zaanan A
Br J Cancer; 2019 Sep; 121(6):434-442. PubMed ID: 31353365
[TBL] [Abstract][Full Text] [Related]
34. Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group.
Goey KKH; Sørbye H; Glimelius B; Adams RA; André T; Arnold D; Berlin JD; Bodoky G; de Gramont A; Díaz-Rubio E; Eng C; Falcone A; Grothey A; Heinemann V; Hochster HS; Kaplan RS; Kopetz S; Labianca R; Lieu CH; Meropol NJ; Price TJ; Schilsky RL; Schmoll HJ; Shacham-Shmueli E; Shi Q; Sobrero AF; Souglakos J; Van Cutsem E; Zalcberg J; van Oijen MGH; Punt CJA; Koopman M
Eur J Cancer; 2018 Sep; 100():35-45. PubMed ID: 29936065
[TBL] [Abstract][Full Text] [Related]
35. Intratumor morphologic and transcriptomic heterogeneity in
Angerilli V; Fontana E; Lonardi S; Sbaraglia M; Borelli B; Munari G; Salmaso R; Guzzardo V; Spolverato G; Pucciarelli S; Pilati P; Hahne JC; Bergamo F; Zagonel V; Dei Tos AP; Sadanandam A; Loupakis F; Valeri N; Fassan M
ESMO Open; 2021 Aug; 6(4):100211. PubMed ID: 34271310
[TBL] [Abstract][Full Text] [Related]
36. The effect of BRAF
Liposits G; Winther SB; Ryg J; Skuladottir H; Möller S; Hofsli E; Shah CH; Poulsen LØ; Berglund Å; Qvortrup C; Osterlund P; Glimelius B; Sorbye H; Pfeiffer P
J Geriatr Oncol; 2024 Mar; 15(2):101632. PubMed ID: 37730481
[No Abstract] [Full Text] [Related]
37. Targeting BRAF V600E in metastatic colorectal cancer: where are we today?
Guerrero RM; Labajos VA; Ballena SL; Macha CA; Lezama MS; Roman CP; Beltran PM; Torrejon AF
Ecancermedicalscience; 2022; 16():1489. PubMed ID: 36819812
[TBL] [Abstract][Full Text] [Related]
38. Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAF
Kotani D; Takashima A; Kato T; Satoh T; Masuishi T; Komatsu Y; Shiozawa M; Esaki T; Izawa N; Takeuchi S; Bando H; Iwasa S; Hasegawa H; Yamaguchi T; Taniguchi H; Ushida Y; Oizaki T; Inoue C; Yoshino T
Clin Colorectal Cancer; 2024 Mar; ():. PubMed ID: 38553360
[TBL] [Abstract][Full Text] [Related]
39. Metastatic Colorectal Cancer Patient With Microsatellite Stability and BRAF
Fang C; Lin J; Zhang T; Luo J; Nie D; Li M; Hu X; Zheng Y; Huang X; Xiao Z
Front Oncol; 2021; 11():652394. PubMed ID: 33987088
[TBL] [Abstract][Full Text] [Related]
40. Comprehensive Landscape of BRAF Variant Classes, Clonalities, and Co-Mutations in Metastatic Colorectal Cancer Using ctDNA Profiling.
Johnson B; Morris V; Wang X; Dasari A; Raghav K; Shen JP; Lee MS; Huey R; Parseghian C; Willis J; Wolff R; Drusbosky LM; Overman MJ; Kopetz S
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
